Hosted by IDTechEx
Advanced Materials World
Posted on November 11, 2026 by  & 

Building Business Models That Scale Industrial Biomanufacturing

Industrial biomanufacturing has the potential to reshape the chemicals industry, but commercial success depends as much on financing as on technology. Understanding viable business models and investment pathways will determine which companies reach commercial scale.
 

 
The global commodity chemical production capacity by industrial biomanufacturing will exceed 8400 kilotonnes by 2027, yet many industrial biomanufacturing companies struggle long before they reach commercial production. The science is often compelling, pilot plants demonstrate technical feasibility, and demand for sustainable chemicals continues to grow. However, the journey from demonstration to large-scale manufacturing remains challenging for the sector, where promising technologies frequently encounter the "valley of death" between innovation and commercial deployment.
 
Industrial biomanufacturing is often discussed in terms of synthetic biology and alternative feedstocks. Equally important, however, is the business model that underpins commercialization. The latest IDTechEx report, "Industrial Biomanufacturing 2027-2037: Technologies, Forecasts, Markets, Players", examines the technologies enabling bio-based chemical production as well as the commercial strategies and challenges that determine whether these technologies reach industrial scale. Understanding how companies finance growth is becoming just as important as understanding the underlying biology.
 
 
Unlike software companies, industrial biomanufacturing cannot scale simply by hiring more engineers or deploying cloud infrastructure. Commercialization requires pilot facilities, demonstration plants, and eventually full-scale manufacturing equipment, each demanding substantial capital investment. Companies therefore adopt different approaches depending on their technology maturity, funding, and long-term objectives.
 
 
Business models in industrial biomanufacturing. Source: IDTechEx.
 
Three business models
 
One strategy is vertical integration, where companies develop their technology while also owning production facilities and manufacturing products themselves. This approach offers greater control over quality and intellectual property and allows companies to capture more value across the production chain. However, it also requires significant capital expenditure and exposes companies to considerable operational risk.
 
Others pursue joint ventures, partnering with established chemical producers, consumer brands, or industrial manufacturers to share both investment costs and commercial risk. These collaborations can provide access to manufacturing expertise, customers, and existing infrastructure while reducing financial exposure for both parties.
 
 
A third approach is licensing, in which companies focus on developing proprietary strains or production technologies before licensing them to established manufacturers. Licensing requires substantially less capital and enables faster expansion, although companies surrender a proportion of future revenue and control over downstream operations.
 
The funding challenge
 
Regardless of business model, financing remains one of the industry's greatest challenges. The transition from proof of concept to commercial production often falls between traditional funding categories. Government funding programs often support research through laboratory and pilot-scale development, but support becomes significantly more limited once companies begin planning commercial production. As a result, many companies must bridge this expensive transition with relatively few financing options.
 
Venture capital typically favors relatively modest investments with rapid growth and defined exit opportunities. Industrial biomanufacturing projects frequently require larger investments and longer development timelines than many venture funds are designed to accommodate. Private equity firms may have the financial capacity to fund large manufacturing facilities but generally expect established businesses with immediate cash generation rather than companies preparing to build their first commercial plant.
 
Several industry leaders have argued that industrial biomanufacturing requires an investment ecosystem more closely resembling pharmaceuticals. In the pharmaceutical sector, larger companies routinely invest in emerging technologies and provide structured exit pathways for investors. Equivalent mechanisms remain limited for industrial biomanufacturing.
 
 
Europe has made notable progress by introducing regulatory frameworks that encourage sustainable investment and improve market predictability. These measures helped position sustainability as an attractive investment theme, contributing to strong investor interest. However, subsequent inflationary pressures and shifting political priorities have slowed investment momentum. Companies that secured funding during this favorable period have generally been better positioned to continue scaling, while newer entrants face a considerably more challenging fundraising environment.
 
Outlook
 
Ultimately, technical innovation alone will not determine the winners in industrial biomanufacturing. Companies must demonstrate that their technologies can deliver commercially competitive production costs, scalable operations, and credible routes to profitability. Investors increasingly expect robust business models that justify the substantial capital required for industrial deployment. The Industrial Biomanufacturing 2027-2037 report from IDTechEx explores these business models and commercial strategies in greater depth, providing insight into how companies can position themselves to attract the patient capital needed to bridge the valley of death and achieve long-term commercial viability.
 
For more details on industrial biomanufacturing market drivers, technology trends, company landscape, and market forecast, see the IDTechEx market report: "Industrial Biomanufacturing 2027-2037: Technologies, Forecasts, Markets, Players". For more information on IDTechEx's other reports and market intelligence offerings, including specialty chemicals biomanufacturing, please visit www.IDTechEx.com/Research.
 
 
IDTechEx guides your strategic business decisions through its Research, Subscription and Consultancy products, helping you profit from emerging technologies. For more information, contact research@IDTechEx.com or visit www.IDTechEx.com.

Authored By:

Technology Analyst

Posted on: November 11, 2026

More IDTechEx Journals